The focus of Cell Therapy Bioprocessing activity is to accelerate the safe, clinical efficacious and cost effective translation of cell therapies into commercial products. The distinctive UCL approach involves taking a ‘whole bioprocess’ view from donor or patient biopsy all the way through to clinical implantation into the patient. To date fundamental bioprocess research in collaboration with clinical groups and companies has supported the development and clinical application of various cell therapies. Achievements include preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue-engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. Future research priorities will focus on novel cell and bioprocess engineering techniques to improve manufacturing efficiency and methods for health technology assessment to support rapid clinical adoption of new cellular and gene therapies.